Vaccine technologies against avian influenza: Current approaches and new directions

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 2261-2294

  Ross, Kathleen A ^a   Huntimer, Lucas M ^b   Vela Ramirez, Julia E ^a   Adams, Justin R ^a   Carpenter, Susan L ^b   Kohut, Marian L ^b   Bronich, Tatiana ^c   Webby, Richard ^d   Legge, Kevin L ^e   Mallapragada, Surya K ^a   Wannemuehler, Michael J ^b   Narasimhan, Balaji ^a  

^a Iowa State University   (United States)

^b IOWA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

Antiviral; H5N1; Highly pathogenic avian influenza; Pandemic; Vaccine

Indexed keywords

VIRUSES;

ANTIVIRAL; AVIAN INFLUENZA; GUANGDONG PROVINCE; H5N1; HIGHLY PATHOGENIC AVIAN INFLUENZAS; INTERVENTION STRATEGY; PANDEMIC; VACCINE TECHNOLOGIES;

VACCINES;

ANTIVIRUS AGENT; AVIAN INFLUENZA VACCINE; DNA VACCINE; HOST FACTOR; NEUTRALIZING ANTIBODY; POLYMER; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR; INFLUENZA VACCINE;

ANTIBODY RESPONSE; AVIAN INFLUENZA; CHINA; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; HISTOPATHOLOGY; HUMAN; INFLUENZA VIRUS A H5N1; NANOTECHNOLOGY; NONHUMAN; PANDEMIC; PARTICLE SIZE; REVERSE GENETICS; REVIEW; T LYMPHOCYTE; ANIMAL; BIRD; IMMUNOLOGY; INFLUENZA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRENDS; VACCINATION; VIROLOGY;

ANIMALS; BIRDS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 84904869711     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1983     Document Type: Review

References (336)

1. C. R. Baskin, H. Bielefeldt-Ohmann, T. M. Tumpey, P. J. Sabourin, J. P. Long, A. García-Sastre, A. E. Tolnay, R. Albrecht, J. A. Pyles, P. H. Olson, L. D. Aicher, E. R. Rosenzweig, K. Murali-Krishna, E. A. Clark, M. S. Kotur, J. L. Fornek, S. Proll, R. E. Palermo, C. L. Sabourin, and M. G. Katze, Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. PNAS 106, 3455 (2009).
2. Q. Ou, Y. Lu, Q. Huang, and X. Cheng, Clinical analysis of 150 cases with the novel influenza A (H1N1) virus infection in Shanghai, China. Biosci. Trends. 3, 127 (2009).
3. S. Lazzari and K. Stöhr, Avian influenza and influenza pandemics. World Health Organization 82, 1 (2004).
4. U.S. Food and Drug Administration, H5N1 influenza virus vaccine questions and answers (2009), 〈www.fda.gov〉.
5. T. Horimoto and Y. Kawakoka, Influenza: Lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3, 591 (2005).
6. R. Sallie, Replicative homeostasis II: Influence of polymerase fidelity on RNA virus quasispecies biology: Implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. Virol. J. 2, 70 (2005).
7. N. J. Cox and K. Subbarao, Global epidemiology of influenza: Past and present. Annu. Rev. Med. 51, 407 (2000).
8. J. S. M. Peiris, C. Y. Cheung, C. Y. H. Leung, and J. M. Nicholls, Innate immune responses to influenza A H5N1: Friend or foe? Trends Immunol. 30, 574 (2009).
9. K. Shinya, M. Ebina, S. Yamada, M. Ono, N. Kasai, and Y. Kawaoka, Avian flu: Influenza virus receptors in the human airway. Nature 440, 435 (2006).
10. S. Yamada, Y. Suzuki, T. Suzuki, M. Q. Le, C. A. Nidom, Y. Sakai-Tagawa, Y. Muramoto, M. Ito, M. Kiso, T. Horimoto, K. Shinya, T. Sawada, M. Kiso, T. Usui, T. Murata, Y. Lin, A. Hay, L. F. Haire, D. J. Stevens, R. J. Russell, S. J. Gamblin, J. J. Skehel, and Y. Kawaoka, Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444, 378 (2006).
11. K. Ungchusak, P. Auewarakul, S. F. Dowell, R. Kitphati, W. Auwanit, P. Puthavathana, M. Uiprasertkul, K. Boonnak, C. Pittayawonganon, N. J. Cox, S. R. Zaki, P. Thawatsupha, M. Chittaganpitch, R. Khontong, J. M. Simmerman, and S. Chunsutthiwat, Probable person-to-person transmission of avian influenza A (H5N1). New Engl. J. Med. 352, 333 (2005).
12. W. Ma, R. E. Kahn, and J. A. Richt, The pig as a mixing vessel for influenza viruses: Human and veterinary implications. J. Mol. Genet. Med. 3, 158 (2009).
13. C. D. O'Donnell and K. Subbarao, The contribution of animal models to the understanding of the host range and virulence of influenza A viruses. Microbes Infect. 13, 502 (2011).
14. S. Herfst, E. J. A. Schrauwen, M. Linster, S. Chutinimitkul, E. de Wit, V. J. Munster, E. M. Sorrell, T. M. Bestebroer, D. F. Burke, D. J. Smith, G. F. Rimmelzwaan, A. D. Osterhaus, and R. A. Fouchier, Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336, 1534 (2012).
15. M. Imai, T. Watanabe, M. Hatta, S. C. Das, M. Ozawa, K. Shinya, G. Zhong, A. Hanson, H. Katsura, S. Watanabe, D. Li, E. Kawakami, S. Yamada, M. Kiso, Y. Suzuki, E. A. Maher, G. Neumann, and Y. Kawaoka, Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420 (2012).
16. K. Y. Yuen, P. K. S. Chan, M. Peiris, D. N. C. Tsang, T. L. Que, K. F. Shortridge, P. T. Cheung, W. K. To, E. T. Ho, R. Sung, and A. F. Chen, Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351, 467 (1998).
17. K.-F. To, P. K. S. Chan, K.-F. Chan, W.-K. Lee, W.-Y. Lam, K.-F. Wong, N. L. Tang, D. N. Tsang, R. Y. Sung, T. A. Buckley, J. S. Tam, and A. F. Cheng, Pathology of fatal human infection associated with avian influenza A H5N1 virus. J. Med. Virol. 63, 242 (2001).
18. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A Virus: A. N. Abdel-Ghafar, T. Chotpitayasunondh, Z. Gao, F. G. Hayden, D. H. Nguyen, M. D. de Jong, A. Naghdaliyev, J. S. Peiris, N. Shindo, S. Soeroso, and T. M. Uyeki, Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358, 261 (2008).
19. M. D. de Jong, B. V. Cam, P. T. Qui, V. M. Hien, T. T. Thanh, N. B. Hue, M. Beld, L. T. Phuong, T. H. Khanh, N. V. V. Chau, T. T. Hien, D. Q. Ha, J. Farrar, and D. Phil, Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352, 686 (2005).
20. J. Gu, Z. Xie, Z. Gao, J. Liu, C. Korteweg, J. Ye, L. T. Lau, J. Lu, Z. Gao, B. Zhang, M. A. McNutt, M. Lu, V. M. Anderson, E. Gong, A. C. Yu, and W. I. Lipkin, H5N1 infection of the respiratory tract and beyond: A molecular pathology study. Lancet 370, 1137 (2007).
21. C. Korteweg and J. Gu, Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am. J. Pathol. 172, 1155 (2008).
22. P. Buchy, S. Mardy, S. Vong, T. Toyoda, J.-T. Aubin, M. Miller, S. Touch, L. Sovann, J. B. Dufourcq, B. Richner, P. V. Tu, N. T. Tien, W. Lim, J. S. Peiris, and S. Van der Weft, Influenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol. 39, 164 (2007).
23. M. D. de Jong, C. P. Simmons, T. T. Thanh, V. M. Hien, G. J. D. Smith, T. N. B. Chau, D. M. Hoang, N. V. Chau, T. H. Khanh, V. C. Dong, P. T. Qui, B. V. Cam, Q. Ha do, J. S. Peiris, N. T. Chinh, T. T. Hien, and J. Farrar, Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203 (2006).
24. J. S. M. Peiris, M. D. de Jong, and Y. Guan, Avian influenza virus (H5N1): A threat to human health. Clin. Microbiol. Rev. 20, 243 (2007).
25. C. Y. Cheung, L. L. M. Poon, A. S. Lau, W. Luk, Y. L. Lau, K. F. Shortridge, S. Gordon, Y. Guan, and J. S. Peiris, Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: A mechanism for the unusual severity of human disease? Lancet 360, 1831 (2002).
26. P. Hofmann, H. Sprenger, A. Kaufmann, A. Bender, C. Hasse, M. Nain, and D. Gemsa, Susceptibility of mononuclear phagocytes to influenza A virus infection and possible role in the antiviral response. J. Leukoc. Biol. 61, 408 (1997).
27. S. Matikainen, J. Pirhonen, M. Miettinen, A. Lehtonen, C. Govenius-Vintola, T. Sareneva, and I. Julkunen, Influenza A and sendai viruses induce differential chemokine gene expression and transcription factor activation in human macrophages. Virology 276, 138 (2000).
28. R. W. Y. Chan, K. M. Yuen, W. C. L. Yu, C. C. C. Ho, J. M. Nicholls, J. S. M. Peiris, and M. C. W. Chan, Influenza H5N1 and H1N1 virus replication and innate immune responses in bronchial epithelial cells are influenced by the state of differentiation. PLoS ONE 5, e8713 (2010).
29. G. F. Rimmelzwaan, T. Kuiken, G. van Amerongen, T. M. Bestebroer, R. A. M. Fouchier, and A. D. M. E. Osterhaus, Pathogenesis of influenza A (H5N1) virus infection in a primate model. J. Virol. 75, 6687 (2001).
30. R. Salomon, E. Hoffmann, and R. G. Webster, Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. PNAS 104, 12479 (2007).
31. J. P. Upham, D. Picktett, T. Irimura, E. M. Anders, and P. C. Reading, Macrophage receptors for influenza A virus: Role of the macrophage galactose-type lectin and mannose receptor in viral entry. J. Virol. 84, 3730 (2010).
32. L. E. Kallal, M. A. Schaller, D. M. Lindell, S. A. Lira, and N. W. Lukacs, CCL20/CCR6 blockade enhances immunity to respiratory syncytial virus by impairing recruitment of dendritic cells. Eur. J. Immunol. 40, 1042 (2010).
33. B. P. Khuntirat, I.-K. Yoon, P. J. Blair, W. S. Krueger, M. Chittaganpitch, S. D. Putnam, K. Supawat, R. V. Gibbons, S. Pattamadilok, P. Sawanpanyalert, G. L. Heil, J. A. Friary, A. W. Cupuano, and G. C. Gray, Evidence for subclinical avian influenza virus infections among rural Thai villagers. Clin. Infect. Dis. 53, e107 (2011).
34. R. J. Cox, K. A. Brokstad, and P. Ogra, Influenza virus: Immunity and vaccination strategies. comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59, 1 (2004).
35. H. J. Ehrlich, M. Muller, H. M. L. Oh, P. A. Tambyah, C. Joukhadar, E. Montomoli, D. Fisher, G. Berezuk, S. Fritsch, A. Low-Baselli, N. Vartian, R. Bobrovsky, B. G. Pavlova, E. M. Pollabauer, O. Kistner, and P. N. Barrett, A clinical trial of a wholevirus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358, 2573 (2008).
36. J. A. McCullers, L-A Van De Velde, K. J. Allison, K. C. Branum, R. J. Webby, and P. M. Flynn, Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin. Infect. Dis. 50, 1487 (2010).
37. P. R. Dormitzer, G. Galli, F. Castellino, H. Golding, S. Khurana, G. Del Giudice, and R. Rappuoli, Influenza vaccine immunology. Immunol. Rev. 239, 167 (2011).
38. K. L. Nichol, K. L. Margolis, A. Lind, M. Murdoch, R. McFadden, M. Hauge, S. Magnan, and M. Drake, Side effects associated with influenza vaccination in healthy working adults: A randomized, placebo-controlled trial. Arch. Intern. Med. 156, 1546 (1996).
39. K. L. Margolis, K. L. Nichol, G. A. Poland, and R. E. Pluhar, Frequency of adverse reactions to influenza vaccine in the elderly. JAMA 264, 1139 (1990).
40. W. Beyer, A. Palache, and A. Osterhaus, Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and meta-analysis of the literature. Clin. Drug Invest. 15, 1 (1998).
41. Centers for Disease Control and Prevention, Key facts about seasonal flu vaccine, 〈www.cdc.gov〉 (2013).
42. D. Fleming, Influenza pandemics and avian flu. BMJ 331, 1066 (2005).
43. J. M. Wood and J. S. Robertson, From lethal virus to live-saving vaccine: Developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2, 842 (2004).
44. R. J. Cox, L. R. Haaheim, J-C Ericsson, A. S. Madhun, and K. A. Brokstad, The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man. Vaccine 25, 6577 (2006).
45. K. A. Brokstad, R. J. Cox, J. Olofsson, R. Jonsson, and L. R. Haaheim, Parenteral influenza vaccination induces a rapid systemic and local immune response. J. Infect. Dis. 171, 198 (1995).
46. S. Abdullah, R. J. C. El-Madhun, and L. R. Haaheim, The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J. Infect. Dis. 180, 1356 (1999).
47. R. J. Cox, E. Mykkeltvedt, H. Sjursen, and L. R. Haaheim, The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine 19, 4743 (2001).
48. T. Guthrie, C. G. Hobbs, V. Davenport, R. E. Horton, R. S. Heyderman, and N. A. Williams, Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J. Infect. Dis. 190, 1927 (2004).
49. C. R. Letter, S. Gravenstein, and J. E. McElhaney, Influenza vaccination is less effective for stimulating a Granzyme B response in older adults. International Congress Series 1219, 713 (2001).
50. J. E. McElhaney, J. W. Hooton, N. Hooton, and R. C. Bleackley, Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23, 3294 (2005).
51. J. J. Treanor, J. D. Campbell, K. M. Zangwill, T. Rowe, and M. Wolff, Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354, 1343 (2006).
52. A. R. Falsey, J. J. Treanor, N. Tornieporth, J. Capellan, and G. J. Gorse, Randomized, double blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200, 172 (2009).
53. F. Geeraedts, N. Goutagny, V. Hornung, M. Severa, A. de Haan, J. Pool, J. Wilschut, K. A. Fitzgerald, and A. Huckriede, Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by toll-like receptor signalling. PLoS Pathog. 4, e1000138 (2008).
54. J.-L. Bresson, C. Perronne, O. Launay, C. Gerdil, M. Saville, J. Wood, K. Hoschler, and M. C. Zambon, Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/ 2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367, 1657 (2006).
55. T. Nolan, P. C. Richmond, N. T. Formica, K. Höschler, M. V. Skeljo, T. Stoney, J. McVernon, G. Hartel, D. C. Sawlwin, J. Bennet, D. Ryan, R. L. Basser, and M. C. Zambon, Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26, 6383 (2008).
56. J. Lin, J. Zhang, X. Dong, H. Fang, J. Chen, N. Su, Q. Gao, Z. Zhang, Y. Liu, Z. Wang, M. Yang, R. Sun, C. Li, S. Lin, M. Ji, Y. Liu, X. Wang, J. Wood, Z. Feng, Y. Wang, and W. Yin, Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A phase I randomised controlled trial. Lancet 368, 991 (2006).
57. W. A. Keitel, C. L. Dekker, C. Mink, J. D. Campbell, K. M. Edwards, .S. M. Patel, D. Y. Ho, H. K. Talbot, K. Guo, D. L. Noah, and H. Hill, Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 27, 6642 (2009).
58. M. H. Snyder, R. F. Betts, D. DeBorde, E. L. Tierney, M. L. Clements, D. Herrington, S. D. Sears, R. Dolin, H. F. Maassab, and B. R. Murphy, Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J. Virol. 62, 488 (1998).
59. T. A. Larson and L. A. Potter, Reviews in medical virology. JAMA 271, 73 (1994).
60. A. L. Suguitan, J. McAuliffe, K. L. Mills, H. Jin, G. Duke, B. Lu, C. J. Luke, B. Murphy, D. E. Swayne, G. Kemble, and K. Subbarao, Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3, e3690 (2006).
61. H. Jin, S. Manetz, J. Leininger, C. Luke, K. Subbarao, B. Murphy, G. Kemble, and K. L. Coelingh, Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 25, 8664 (2007).
62. R. A. Karron, K. Talaat, C. Luke, K. Callahan, B. Thumar, S. DiLorenzo, J. McAuliffe, E. Schappell, A. Suguitan, K. Mills, G. Chen, E. Lamirande, K. Coelingh, H. Jin, B. R. Murphy, G. Kemble, and K. Subbarao, Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27, 4953 (2009).
63. L. Rudenko, J. Desheva, S. Korovkin, A. Mironov, A. Rekstin, E. Grigorieva, S. Donina, A. Gambaryan, and A. Katlinsky, Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I and II clinical trials). Influenza Other Respi. Viruses 2, 203 (2008).
64. J. Shi, Z. Wen, J. Guo, Y. Zhang, G. Deng, Y. Shu, D. Wang, Y. Jiang, Y. Kawaoka, Z. Bu, and H. Chen, Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice. Antivir. Res. 93, 346 (2012).
65. Y. H. Jang, Y. H. Byun, Y. J. Lee, Y. H. Lee, K.-H. Lee, and B. L. Seong, Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J. Virol. 86, 5953 (2012).
66. R. B. Belshe, K. M. Edwards, T. Vesikari, S. V. Black, R. E. Walker, M. Hultquist, G. Kemble, and E. M. Connor, Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685 (2007).
67. R. B. Belshe, W. C. Gruber, P. M. Mendelman, I. Cho, K. Reisinger, S. L. Block, J. Wittes, D. Iacuzio, P. Piedra, J. Treanor, J. King, K. Kotloff, D. I. Bernstein, F. G. Hayden, K. Zangwill, L. Yan, and M. Wolff, Efficacy of vaccination with live attenuated, coldadapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136, 168 (2000).
68. M. E. Halloran, P. A. Piedra, J. I. M. Longini, M. J. Gaglani, B. Schmotzer, C. Fewlass, G. B. Herschler, and W. P. Glezen, Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 25, 4038 (2007).
69. I. Meunier, S. Pillet, J. N. Simonsen, and V. von Messling, Influenza pathogenesis: Lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Crit. Care Med. 38, e21 (2010).
70. M. D. de Jong, T. T. Tran, H. K. Truong, M. H. Vo, G. J. Smith, V. C. Nguyen, V. C. Bach, T. Q. Phan, Q. H. Do, Y. Guan, J. S. Peiris, T. H. Tran, and J. Farrar, Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353, 2667 (2005).
71. N. J. Cox and K. Subbarao, Global epidemiology of influenza: Past and present. Annu. Rev. Med. 51, 407 (2000).
72. E. A. Govorkova, I. A. Leneva, O. G. Goloubeva, K. Bush, and R. G. Webster, Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45, 2723 (2001).
73. E. A. Govorkova, N. A. Ilyushina, D. A. Boltz, A. Douglas, N. Yilmaz, and R. G. Webster, Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51, 1414 (2007).
74. Q. M. Le, M. Kiso, K. Someya, Y. T. Sakai, T. H. Nguyen, K. H. L. Nguyen, N. D. Pham, H. H. Ngyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka, Avian flu: Isolation of drug-resistant H5N1 virus. Nature 437, 1108 (2005).
75. D. A. Boltz, B. Douangngeun, P. Phommachanh, S. Sinthasak, R. Mondry, C. Obert, P. Seiler, R. Keating, Y. Suzukia, H. Hiramatsu, E. A. Govorkova, and R. G. Webster, Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J. Gen. Virol. 91, 949 (2010).
76. I. A. Leneva, O. Goloubeva, R. J. Fenton, M. Tisdale, and R. G. Webster, Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob. Agents Chemother. 45, 1216 (2001).
77. K. J. Stittelaar, M. Tisdale, G. van Amerongen, R. F. van Lavieren, F. Pistoor, J. Simon, and A. D. Osterhaus, Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antivir. Res. 80, 225 (2008).
78. A. J. Hay, A. J. Wolstenholme, J. J. Skehel, and M. H. Smith, The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4, 3021 (1985).
79. G. He, J. Qiao, C. Dong, C. He, L. Zhao, and Y. Tian, Amantadineresistance among H5N1 avian influenza viruses isolated in Northern China. Antivir. Res. 77, 72 (2008).
80. M. T. Le, H. F. Wertheim, H. D. Nguyen, W. Taylor, P. V. Hoang, C. D. Vuong, H. L. K. Nguyen, H. H. Nguyen, T. Q. Nguyen, T. V. Nguyen, T. D. Van, B. T. Ngoc, T. N. Bui, B. G. Nguyen, L. T. Nguyen, S. T. Luong, P. H. Phan, H. V. Pham, T. Nguyen, A. Fox, C. V. Nguyen, H. Q. Do, M. Crusat, J. Farrar, H. T. Nguyen, M. D. de Jong, and P. Horby, Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS One 3, e3339 (2008).
81. R. Tang, R. N. Palumbo, W. Ji, and C. Wang, Poly(ortho ester amides): Acid-labile temperature-responsive copolymers for potential biomedical applications. Biomacromolecules 10, 722 (2009).
82. N. Van Hoeven, J. A. Belser, K. J. Szretter, H. Zeng, P. Staeheli, D. E. Swayne, J. M. Katz, and T. M. Tumpey, Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: Antiviral potential of exogenous alpha interferon to reduce virus shedding. J. Virol. 83, 2851 (2009).
83. D. Kugel, G. Kochs, K. Obojes, J. Roth, G. P. Kobinger, D. Kobasa, O. Haller, P. Staeheli, and V. von Messling, Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J. Virol. 83, 3843 (2009).
84. R. Salomon, E. Hoffmann, and R. G. Webster, Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. PNAS 104, 12479 (2007).
85. J. Cinatl, M. Michaelis, and H. W. Doerr, The threat of avian influenza A (H5N1). Part III: Antiviral therapy. Med. Microbiol. Immun. 196, 203 (2007).
86. D. S. C. Hui, Influenza A/H5N1 infection: Other treatment options and issues. Respirology 13, S22 (2008).
87. N. J. White, R. G. Webster, E. A. Govorkova, and T. M. Uyeki, What is the optimal therapy for patients with H5N1 influenza? PLoS Med. 6, e1000091 (2009).
88. L. C. Jennings, A. S. Monto, P. K. Chan, T. D. Szucs, and K. G. Nicholson, Stockpiling prepandemic influenza vaccines: A new cornerstone of pandemic preparedness plans. Lancet Infect. Dis. 8, 650 (2008).
89. L. R. Smith, M. K. Wloch, M. Ye, L. R. Reyes, S. Boutsaboualoy, C. E. Dunne, J. A. Chaplin, D. Rusalov, A. P. Rolland, C. L. Fisher, M. S. Al-Ibrahim, M. L. Kabongo, R. Steigbigel, R. B. Belshe, E. R. Kitt, A. H. Chu, and R. B. Moss, Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28, 2565 (2010).
90. J. H. Kim and J. Jacob, DNA vaccines against influenza viruses. Curr. Top. Microbiol. Immunol. 333, 197 (2009).
91. C. Gerdil, The annual production cycle for influenza vaccine. Vaccine 21, 1776 (2003).
92. E. Hoffmann, G. Neumann, Y. Kawaoka, G. Hobom, and R. G. Webster, A DNA transfection system for generation of influenza A virus from eight plasmids. PNAS 97, 6108 (2000).
93. G. Neumann, T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hoborn, and Y. Kawaoka, Generation of influenza A viruses entirely from cloned cDNAs. PNAS 96, 9345 (1999).
94. E. Hoffmann, S. Krauss, D. Perez, R. Webby, and R. G. Webster, Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20, 3165 (2002).
95. K. Subbarao, H. Chen, D. Swayne, L. Mingay, E. Fodor, G. Brownlee, X. Xu, X. Lu, J. Katz, N. Cox, and Y. Matsuoka, Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305, 192 (2003).
96. E. J. Jung, K. H. Lee, and B. L. Seong, Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Exp. Mol. Med. 42, 116 (2010).
97. C. Nicolson, D. Major, J. M. Wood, and J. S. Robertson, Generation of influenza vaccine viruses on Vero cells by reverse genetics: An H5N1 candidate vaccine strain produced under a quality system. Vaccine 23, 2943 (2005).
98. R. J. Webby, D. R. Perez, J. S. Coleman, Y. Guan, J. H. Knight, E. A. Govorkova, L. R. McClain-Moss, J. S. Peiris, J. E. Rehg, E. I. Tuomanen, and R. G. Webster, Responsiveness to a pandemic alert: Use of reverse genetics for rapid development of influenza vaccines. Lancet 363, 1099 (2004).
99. M. K. Howard, O. Kistner, and P. N. Barrett, Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 389, 569 (2008).
100. M. Ozawa, H. Goto, T. Horimoto, and Y. Kawaoka, An adenovirus vector-mediated reverse genetics system for influenza A virus generation. J. Virol. 81, 9556 (2007).
101. O. Kistner, M. K. Howard, M. Spruth, W. Wodal, P. Brühl, M. Gerencer, B. A. Crowe, H. Savidis-Dacho, I. Livey, M. Reiter, I. Mayerhofer, C. Tauer, L. Grillberger, W. Mundt, F. G. Falkner, and P. N. Barrett, Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25, 6028 (2007).
102. R. G. Webster, R. J. Webby, E. Hoffmann, J. Rodenberg, M. Kumar, H-J Chu, P. Seiler, S. Krauss, and T. Songserm, The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens. Virology 351, 303 (2006).
103. G. Tian, S. Zhang, Y. Li, Z. Bu, P. Liu, J. Zhou, C. Li, J. Shi, K. Yu, and H. Chen, Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics. Virology 341, 153 (2005).
104. A. L. Suguitan, M. P. Marino, P. D. Desai, L.-M. Chen, Y. Matsuoka, R. O. Donis, H. Jin, D. E. Swayne, G. Kemble, and K. Subbarao, The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology 395, 280 (2009).
105. S. Fan, Y. Gao, K. Shinya, C. K. Li, Y. Li, J. Shi, Y. Jiang, Y. Suo, T. Tong, G. Zhong, J. Song, Y. Zhang, G. Tian, Y. Guan, X. N. Xu, Z. Bu, Y. Kawaoka, and H. Chen, Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog. 5, e1000409 (2009).
106. A. K. Sharma and G. K. Khuller, DNA vaccines: Future strategies and relevance to intracellular pathogens. Immunol. Cell. Biol. 79, 537 (2001).
107. H. L. Davis, M.-L. Michel, and R. G. Whalen, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2, 1847 (1993).
108. T. Kawai and S. Akira, The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373 (2010).
109. J. T. Holt, A 'senseless' immune response to DNA. Nat. Med. 1, 407 (1995).
110. D. J. Shedlock and D. B. Weiner, DNA vaccination: Antigen presentation and the induction of immunity. J. Leukoc. Biol. 68, 793 (2000).
111. H. Shirota, L. Petrenko, C. Hong, and D. M. Klinman, Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J. Immunol. 179, 329 (2007).
112. Z. Xiang and H. C. J. Ertl, Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2, 129 (1995).
113. E. Okada, S. Sasaki, N. Ishii, I. Aoki, T. Yasuda, K. Nishioka, J. Fukushima, J. Miyazaki, B. Wahren, and K. Okuda, Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159, 3638 (1997).
114. J. S. Boyle, J. L. Brady, and A. M. Lew, Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392, 408 (1998).
115. Y. Chow, W. Huang, W. Chi, Y. Chu, and M. Tao, Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71, 169 (1997).
116. X. de Andrés, R. Reina, J. Ciriza, H. Crespo, I. Glaria, H. Ramírez, M. J. Grilló, M. M. Pérez, V. André sdóttir, S. Rosati, M. Suzan-Monti, L. Luján, B. A. Blacklaws, G. D. Harkiss, D. de Andrés, and B. Amorena, Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus. Vaccine 27, 4591 (2009).
117. G. J. Logan, L. Wang, M. Zheng, S. L. Ginn, R. L. Coppel, and I. E. Alexander, Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules. Gene Ther. 16, 200 (2008).
118. A, Patel, K. Tran, M. Gray, Y. Li, Z. Ao, X. Yao, D. Kobasa, and G. P. Kobinger, Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 27, 3083 (2009).
119. S. L. Epstein, W.-P. Kong, J. A. Misplon, C.-Y. Lo, T. M. Tumpey, L. Xu, and G. J. Nabel, Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23, 5404 (2005).
120. M.-W. Chen, T.-J. R. Cheng, Y. Huang, J.-T. Jan, S.-H. Ma, A. L. Yu, C. H. Wong, and D. D. Ho, A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. PNAS 105, 13538 (2008).
121. S. S. Rao, W.-P. Kong, C.-J. Wei, N. Van Hoeven, J. P. Gorres, M. Nason, H. Andersen, T. M. Tumpey, and G. J. Nabel, Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 5, e9812 (2010).
122. P. A. Lalor, R. J. Webby, J. Morrow, D. Rusalov, D. C. Kaslow, A. Rolland, and L. R. Smith, Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 197, 1643 (2008).
123. K. Xu, Z-Y. Ling, L. Sun, Y. Xu, C. Bian, Y. He, W. Lu, Z. Chen, and B. Sun, Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol. 24, 45 (2011).
124. M. Luo, X. Qu, R. Pan, D. Zhu, Y. Zhang, J. Wu, and Z. Pan, The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice. Vaccine 29, 2561 (2011).
125. D. J. Laddy, J. Yan, M. Kutzler, D. Kobasa, G. P. Kobinger, A. S. Khan, J. Greenhouse, N. Y. Sardesai, R. Draghia-Akli, and D. B. Weiner, Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 3, e2517 (2008).
126. L. A. Perrone, A. Ahmad, V. Veguilla, X. Lu, G. Smith, J. M. Katz, P. Pushko, and T. M. Tumpey, Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83, 5726 (2009).
127. R. A. Bright, D. M. Carter, C. J. Crevar, F. R. Toapanta, J. D. Steckbeck, K. S. Cole, N. M. Kumar, P. Pushko, G. Smith, T. M. Tumpey, and T. M. Ross, Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3, e1502 (2008).
128. A. Pandey, N. Singh, and S. K. Mittal, Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum. Vaccines 6, 178 (2010).
129. S.-M. Kang, J.-M. Song, F.-S. Quan, and R. W. Compans, Influenza vaccines based on virus-like particles. Virus Res. 143, 140 (2009).
130. R. W. Compans and W. A. Orenstein, Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. 333, 269 (2009).
131. C. Reichel, C. Ruehland, C. O. A. Reiser, and J. Hess, Proteinbased nanosystems: Virus-like-particles in modern vaccine development. J. Biomed. Nanotechnol. 2, 186 (2006).
132. H. Song, V. Wittman, A. Byers, T. Tapia, B. Zhou, W. Warren, P. Heaton, and K. Connolly, In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 28, 5524 (2010).
133. S.-M. Kang, D.-G. Yoo, A. S. Lipatov, J.-M. Song, C. T. Davis, F.-S. Quan, L.-M. Chen, R. O. Donis, and R. W. Compans, Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 4, e4667 (2009).
134. P. Tao, M. Luo, D. Zhu, S. Qu, Z. Yang, M. Gao, D. Guo, and Z. Pan, Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol. 22, 273 (2009).
135. J.-M. Song, J. Hossain, D.-G. Yoo, A. S. Lipatov, C. T. Davis, F.-S. Quan, L. M. Chen, R. J. Hogan, R. O. Donis, R. W. Compans, and S. M. Kang, Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405, 165 (2010).
136. J.-M. Song, Y.-C. Kim, A. S. Lipatov, M. Pearton, C. T. Davis, D.-G. Yoo, K. M. Park, L. M. Chen, F. S. Quan, J. C. Birchall, R. O. Donis, M. R. Prausnitz, R. W. Compans, and S. M. Kang, Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B and T cell responses in mice. Clin. Vaccine Immunol. 17, 1381 (2010).
137. F.-S. Quan, Y.-C. Kim, A. Vunnava, D.-G. Yoo, J.-M. Song, M. R. Prausnitz, R. W. Compans, and S. M. Kang, Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J. Virol. 84, 7760 (2010).
138. B. M. Giles, C. J. Crevar, D. M. Carter, S. J. Bissel, S. Schultz- Cherry, C. A. Wiley, and T. M. Ross, A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J. Infect. Dis. 205, 1562 (2012).
139. J.-K. Park, D.-H. Lee, H.-N. Youn, M.-S. Kim, Y.-N. Lee, S.-S. Yuk, T. H. Lim, J. H. Jang, J. H. Kwon, B. Y. Kim, S. M. Kang, B. L. Seong, J. B. Lee, S. Y. Park, I. S. Choi, and C. S. Song, Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respi. Virus 7, 340 (2013).
140. L. A. H. M. Cornelissen, R. P. de Vries, E. A. de Boer-Luijtze, A.
141. C.-J. Wei, L. Xu, W.-P. Kong, W. Shi, K. Canis, J. Stevens, Z. Y. Yang, A. Dell, S. M. Haslam, I. A. Wilson, and G. J. Nabel, Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82, 6200 (2008).
142. M. Prabakaran, S. Madhan, N. Prabhu, J. Qiang, and J. Kwang, Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J. Virol. 84, 3201 (2010).
143. L. Guo, M. Zheng, Y. Ding, D. Li, Z. Yang, H. Wang, Q. Chen, Z. Sui, F. Fang, and Z. Chen, Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch. Virol. 155, 1765 (2010).
144. G. E. Price, M. R. Soboleski, C.-Y. Lo, J. A. Misplon, C. Pappas, K. V. Houser, T. M. Tumpey, and S. L. Epstein, Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27, 6512 (2009).
145. Y. Adar, Y. Singer, R. Levi, E. Tzehoval, S. Perk, C. Banet-Noach, S. Nagar, R. Arnon, and T. Ben-Yedidia, A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27, 2099 (2009).
146. Y. Shoji, H. Bi, K. Musiychuk, A. Rhee, A. Horsey, G. Roy, B. Green, M. Shamloul, C. E. Farrance, B. Taggart, N. Mytle, N. Ugulava, S. Rabindran, V. Mett, J. A. Chichester, and V. Yusibov, Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 27, 1087 (2009).
147. Q. M. Xie, J. Ji, L. Q. Du, Y. C. Cao, L. Wei, C. Y. Xue, J. P. Qin, J. Y. Ma, and Y. Z. Bi, Preparation and immune activity analysis of H5N1 subtype avian influenza virus recombinant protein-based vaccine. Poult. Sci. 88, 1608 (2009).
148. S. M. Tompkins, Z.-S. Zhao, C.-Y. Lo, J. A. Misplon, T. Liu, Z. Ye, R. J. Hogan, Z. Wu, K. A. Benton, T. M. Tumpey, and S. L. Epstein, Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13, 426 (2007).
149. Y. J. Lin, M. C. Deng, S. H. Wu, Y. L. Chen, H. C. Cheng, C. Y. Chang, M. S. Lee, M. S. Chien, and C. C. Huang, Baculovirus-derived hemagglutinin vaccine protects chickens from lethal homologous virus H5N1 challenge. J. Vet. Med. Sci. 70, 1147 (2008).
150. W. C. Weldon, B.-Z. Wang, M. P. Martin, D. G. Koutsonanos, I. Skountzou, and R. W. Compans, Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS ONE 5, e12466 (2010).
151. S.-C. Lin, M.-H. Huang, P.-C. Tsou, L.-M. Huang, P. Chong, and S.-C. Wu, Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS ONE 6, e20052 (2011).
152. M. M. Cox, P. A. Patriarca, and J. Treanor, FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi. Virus 2, 211 (2008).
153. G. J. Tobin, J. D. Trujillo, R. V. Bushnell, G. Lin, A. R. Chaudhuri, J. Long, J. Barrera, L. Pena, M. J. Grubman, and P. L. Nara, Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26, 6189 (2008).
154. R. R. Garrity, G. Rimmelzwaan, A. Minassian, W. P. Tsai, G. Lin, J. J. de Jong, J. Goudsmit, and P. L. Nara, Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159, 279 (1997).
155. P. L. Nara and D. S. Roland, Deceptive imprinting: Insights into mechanisms of immune evasion and vaccine development. Adv. Veter. Med. AP. 41, 115 (1999).
156. D. E. Swayne, M. Garcia, J. R. Beck, N. Kinney, and D. L. Suarez, Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert. Vaccine 18, 1088 (2000).
157. J. Steel, A. C. Lowen, T. T. Wang, M. Yondola, Q. Gao, K. Haye, A. García-Sastre, and P. Palese, Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 1, e00018-10-e-10 (2010).
158. M. Bublot, N. Pritchard, J. S. Cruz, T. R. Mickle, P. Selleck, and D. E. Swayne, Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge. Avian Dis. 51, 498 (2007).
159. M. Mingxiao, J. Ningyi, W. Zhenguo, W. Ruilin, F. Dongliang, Z. Min, Y. Gefen, L. Chang, J. Leili, J. Kuoshi, and Z. Yingiiu, Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18. Vaccine 24, 4304 (2006).
160. J. H. C. M. Kreijtz, Y. Suezer, G. van Amerongen, G. de Mutsert, B. S. Schnierle, J. M. Wood, T. Kuiken, R. A. Fouchier, J. Lower, A. D. Osterhaus, G. Sutter, and G. F. Rimmelzwaan, Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195, 1598 (2007).
161. C. S. Kyriakis, A. De Vleeschauwer, F. Barbe, M. Bublot, and K. Van Reeth, Safety, immunogenicity and efficacy of poxvirusbased vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 27, 2258 (2009).
162. K. R. Van Kampen, Z. Shi, P. Gao, J. Zhang, K. W. Foster, D.-T. Chen, D. Marks, C. A. Elmets, and D. C. Tang, Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23, 1029 (2005).
163. L. A. Cornelissen, O. S. de Leeuw, M. G. Tacken, H. C. Klos, R. P. de Vries, E. A. de Boer-Luijtze, D. J. van Zoelen-Bos, A. Rigter, P. J. Rottier, R. J. Moormann, and C. A. de Haan, Protective efficacry of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice. PLoS ONE 7, e44447 (2012).
164. A. Lardinois, M. Steensels, B. Lambrecht, N. Desloges, M. Rahaus, D. Rebeski, and T. van den Berg, Potency of a recombinant NDVH5 vaccine against various HPAI H5N1 virus challenges in SPF chickens. Avian Dis. 56, 928 (2012).
165. E. Niqueux, O. Guionie, M. Amelot, and V. Jestin, Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus. Vaccine 31, 4121 (2013).
166. S. Yang, S. Niu, Z. Guo, Y. Yuan, K. Xue, S. Liu, and H. Jin, Crossprotective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus. Virol. J. 10, 291 (2013).
167. Z. Wang, Q. Yu, J. Gao, and Q. Yang, Mucosal and systemic immune responses induced by recombinant lactobacillus expressing the hemagglutinin of the avian influenza virus. Clin. Vaccine Immunol. 19, 174 (2012).
168. S. Sambhara and G. A. Poland, Breaking the immunogenicity barrier of bird flu vaccines. Lancet 370, 544 (2007).
169. I. Leroux-Roels, A. Borkowski, T. Vanwolleghem, M. Dramé, F. Clement, E. Hons, J. M. Devaster, and G. Leroux-Roels, Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370, 580 (2007).
170. B. Mastelic, S. Ahmed, W. M. Egan, G. Del Giudice, H. Golding, I. Gust, P. Neels, S. G. Reed, R. L. Sheets, C. A. Siegrist, and P. H. Lambert, Mode of action of adjuvants: Implications for vaccine safety and design. Biologicals 38, 594 (2010).
171. G. Leroux-Roels, Unmet needs in modern vaccinology: Adjuvants to improve the immune response. Vaccine 28, C25 (2010).
172. H. E. Sahly, MF59 as a vaccine adjuvant: A review of safety and immunogenicity. Expert Rev. Vaccines 9, 1135 (2010).
173. A. Ninomiya, M. Imai, M. Tashiro, and T. Odagiri, Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25, 3554 (2007).
174. C. Ruat, C. Caillet, A. Bidaut, J. Simon, and A. D. M. E. Osterhaus, Vaccination of macaques with adjuvanted formalininactivated influenza A virus (H5N1) vaccines: Protection against H5N1 challenge without disease enhancement. J. Virol. 82, 2565 (2008).
175. N. J. Carter and G. L. Plosker, Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix(TM)]: A review of its use as an active immunization against influenza A subtype H5N1 virus. Bio. Drugs 22, 279 (2008).
176. R. W. Compans, W. A. Orenstein, R. L. Atmar, and W. A. Keitel, Adjuvants for pandemic influenza vaccines, Vaccines for Pandemic Influenza, Springer, Berlin, Heidelberg (2009), pp. 323-344.
177. I. Leroux-Roels 323-344 G. Leroux-Roels, Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 8, 401 (2009).
178. I. Leroux-Roels, F. Roman, S. Forgus, C. Maes, F. De Boever, M. Dramé, P. Gillard, R. van der Most, M. Van Mechelen, E. Hanon, and G. Lerous-Roels, Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine 28, 849 (2010).
179. W. Keitel, N. Groth, M. Lattanzi, M. Praus, A. K. Hilbert, A. Borkowski, and T. F. Tsai, Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28, 840 (2010).
180. S. Khurana, W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, M. T. Rock, K. M. Edwards, G. Del Guidice, R. Rappuoli, and H. Golding, Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15a5 (2010).
181. J. G. M. Heldens, H. L. Glansbeek, L. A. T. Hilgers, B. Haenen, K. J. Stittelaar, A. D. M. E. Osterhaus, and J. F. van den Bosch, Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. Vaccine 28, 8125 (2010).
182. R. Bodewes, J. H. C. M. Kreijtz, G. van Amerongen, M. M. Geelhoed-Mieras, R. J. Verburgh, J. G. M. Heldens, J. Bedwell, J. M. van den Brand, T. Kuiken, C. A. van Baalen, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan, A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J. Virol. 84, 7943 (2010).
183. G. F. Rimmelzwaan, E. C. J. Claas, G. Van Amerongen, J. C. de Jong, and A. D. M. E. Osterhaus, ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 17, 1355 (1999).
184. S. Kodihalli, V. Sivanandan, K. V. Nagaraja, D. Shaw, and D. A. Halvorson, A type-specific avian influenza virus subunit vaccine for turkeys: Induction of protective immunity to challenge infection. Vaccine 12, 1467 (1994).
185. Y. Xie, H.-X. Sun, and D. Li, Platycodin D improves the immunogenicity of newcastle disease virus-based recombinant avian influenza vaccine in mice. Chem. Biodivers 7, 677 (2010).
186. F. Steinhagen, T. Kinjo, C. Bode, and D. M. Klinman, TLR-based immune adjuvants. Vaccine 29, 3341 (2011).
187. H. J. Warshakoon, J. D. Hood, M. R. Kimbrell, S. Malladi, W. Y. Wu, N. Shukla, G. Agnihotri, D. Sil, and S. A. David, Potential adjuvantic properties of innate immune stimuli. Hum. Vaccines 5, 381 (2009).
188. A. Lahiri, P. Das, and D. Chakravortty, Engagement of TLR signaling as adjuvant: Towards smarter vaccine and beyond. Vaccine 26, 6777 (2008).
189. J. P. Wong, M. E. Christopher, S. Viswanathan, N. Karpoff, X. Dai, D. Das, L. Q. Sun, M. Wang, and A. M. Salazar, Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27, 3481 (2009).
190. M. Isaka, Y. Zhao, E. Nobusawa, S. Nakajima, K. Nakajima, Y. Yasuda, H. Matsui, T. Hasegawa, J. Maeyama, K. Morokuma, K. Ohkuma, and K. Tochikubo, Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice. Microbiol. Immunol. 52, 55 (2008).
191. Y.-F. Lau, L.-H. Tang, A. W. McCall, E.-E. Ooi, and K. Subbarao, An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J. Virol. 84, 8639 (2010).
192. A. Sjoblom-Hallen, U. Marklund, A. Nerstedt, K. Schon, L. Ekman, P. Bergqvist, B. Lowenadler, and N. Y. Lycke, Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant. Mucosal Immunol. 3, 374 (2010).
193. M. Prabakaran, S. Velumani, F. He, A. K. Karuppannan, G. Y. Geng, L. K. Yin, and J. Kwang, Protective immunity against influenza H5N1 virus challenge in mice by intranasal coadministration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 380, 412 (2008).
194. P. Yang, C. Tang, D. Luo, Z. Zhan, L. Xing, Y. Duan, W. Jia, D. Peng, X. Liu, and X. Wang, Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. Vet. Microbiol. 146, 17 (2010).
195. G. M. Glenn, D. N. Thomas, K. L. Poffenberger, D. C. Flyer, L. R. Ellingsworth, B. H. Andersen, and S. A. Frech, Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 27, G60 (2009).
196. W. Quintilio, F. S. Kubrusly, D. Iourtov, C. Miyaki, M. A. Sakauchi, F. Lúcio, C. Dias Sde, C. S. Takata, E. N. Miyaji, H. G. Hiqashi, L. C. Leite, and I. Raw, Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 27, 4219 (2009).
197. M.-H. Huang, S.-C. Lin, C.-H. Hsiao, H.-J. Chao, H.-R. Yang, C.-C. Liao, P.-W. Chuang, H.-P. Wu, C.-Y. Huang, C.-H. Leng, S.-J. Liu, H.-W. Chen, A.-H. Chou, A. Y.-C. Hu, and P. Chong, Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS ONE 5, e12279 (2010).
198. M.-H. Huang, C.-Y. Huang, S.-C. Lin, J.-H. Chen, C.-C. Ku, A.-H. Chou, S. J. Liu, H. W. Chen, P. Chong, and C. H. Leng, Enhancement of potent antibody and T-cell responses by a singledose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect. 11, 654 (2009).
199. Y. Asahi-Ozaki, S. Itamura, T. Ichinohe, P. Strong, S.-I. Tamura, H. Takahashi, H. Sawa, M. Moriyama, M. Tashiro, T. Sata, T. Kurata, and H. Hasegawa, Intranasal administration of adjuvantcombined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect. 8, 2706 (2006).
200. T. Ichinohe, I. Watanabe, S. Ito, H. Fujii, M. Moriyama, S. Tamura, H. Takahashi, H. Sawa, J. Chiba, T. Kurata, T. Sata, and H. Hasegawa, Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79, 2910 (2005).
201. S. G. Reed, S. Bertholet, R. N. Coler, and M. Friede, New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23 (2009).
202. B. N. Lambrecht, M. Kool, M. A. Willart, and H. Hammad, Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23 (2009).
203. V. Bhardwaj, S. Hariharan, I. Bala, A. Lamprecht, N. Kumar, R. Panchagnula, and M. Kumar, Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery. J. Biomed. Nanotechnol. 1, 235 (2005).
204. S. Y. Seong and P. Matzinger, Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469 (2004).
205. W. Jiang, R. K. Gupta, M. C. Deshpande, and S. P. Schwendeman, Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliver. Rev. 57, 391 (2005).
206. J. Panyam and V. Labhasetwar, Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliver. Rev. 55, 329 (2003).
207. S. Hamdy, A. Haddadi, R. W. Hung, and A. Lavasanifar, Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug Deliver. Rev. 63, 943 (2011).
208. A. Kumari, S. K. Yadav, and S. C. Yadav, Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surface B 75, 1 (2010).
209. N. K. Gupta, P. Tomar, V. Sharma, and V. K. Dixit, Development and characterization of chitosan coated poly-(e-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 29, 9026 (2011).
210. A. L. Galloway, A. Murhpy, J. M. DeSimone, J. Di, J. P. Hermann, M. E. Hunter, J. P Kindig, F. J. Malinoski, M. A. Rumley, D. M. Stoltz, T. S. Templeman, and B. Hubby, Development of a nanoparticle-based influenza vaccine using the PRINT technology. Nanomedicine 9, 523 (2013).
211. N. L. Pham, L. L. Pewe, C. J. Fleenor, R. A. Langlois, K. L. Legge, V. P. Badovinac, and J. T. Harty, Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. PNAS 107, 12198 (2010).
212. K. Zhao, G.-X. Li, Y.-Y. Jin, H.-X. Wei, Q.-S. Sun, T.-T. Huang, Y.-F. Wang, and G.-Z. Tong, Preparation and immunological effectiveness of a Swine influenza DNA vaccine encapsulating in PLGA microspheres. J. Microencapsul. 27, 178 (2010).
213. H. Sneh-Edri, D. Likhtenshtein, and D. Stepensky, Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross presentation in vitro. Mol. Pharm. 8, 1266 (2011).
214. C. Gong, Y. Xie, Q. Wu, Y. Wang, S. Deng, D. Xiong, L. Liu, X. M. Z. Qian, and Y. Wei, Improving anti-tumor activity with polymeric micells entrapping paclitaxel in pulmonary carcinoma. Nanoscale 4, 6004 (2012).
215. J. Singh, S. Pandit, V. W. Bramwell, and H. O. Alpar, Diphtheria toxoid loaded poly-(e-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38, 96 (2006).
216. J. Heller and J. Barr, Poly(ortho ester)-From concept to reality. Biomacromolecules 5, 1625 (2004).
217. E. E. Falco, M. Patel, and J. P. Fisher, Recent developments in cyclic acetal biomaterials for tissue engineering applications. Pharmaceut. Res. 25, 2348 (2008).
218. T. T. Beaudette, E. M. Bachelder, J. A. Cohen, A. C. Obermeyer, K. E. Broaders, J. M. Frechet, E. S. Kang, I. Mende, W. W. Tseng, M. G. Davidson, and E. G. Engleman, In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol. Pharm. 6, 1160 (2009).
219. J. J. Escovar-Chavez, M. Lopez-Cervantes, A. Naik, Y. N. Kalia, D. Quintanar-Guerrero, and A. Ganem-Quintanar, Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J. Pharm. Pharm. Sci. 9, 339 (2006).
220. J. E. Matthew, Y. L. Nazario, S. C. Roberts, and S. R. Bhatia, Effect of mammalian cell culture medium on the gelation properties of Pluronic F127. Biomaterials 23, 4615 (2002).
221. B. Zhang, F. Jia, M. Q. Fleming, and S. K. Mallapragada, Injectable self-assembled block copolymers for sustained gene and drug codelivery: An in vitro study. Int. J. Pharm. 427, 88 (2012).
222. C. Manoharan and J. Singh, Evaluation of polyanhydride microspheres for basal insulin delivery: Effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo adsorption and bioactivity in diabetic rats. J. Pharm. Sci. 98, 4237 (2009).
223. J. P. Jain, S. Modi, A. J. Domb, and N. Kumar, Role of polyanhydrides as localized drug carriers. J. Controlled Release 103, 541 (2005).
224. J. Griffin, R. Delgado-Rivera, S. Meiners, and K. E. Uhrich, Slicylic acid-derived poly(anhydride-ester) electrospun fibers designed for regenerating the peripheral nervous system. J. Biomed. Mater. Res. A 97, 230 (2011).
225. M. P. Torres, A. S. Determan, G. L. Anderson, S. K. Mallapragada, and B. Narasimhan, Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 28, 108 (2007).
226. D. S. Katti, S. Lakshmi, R. Langer, and C. T. Laurencin, Toxicity, biodegradation and elimination of polyanhydrides. Adv. Drug Deliver. Rev. 54, 933 (2002).
227. K. A. Ross, S. L. Haughney, L. K. Petersen, P. Boggiatto, M. J. Wannemuehler, and B. Narasimhan, Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours. Adv. Healthc. Mater. (2014), In press, DOI: 10.1002/adhm.201300525.
228. L. Huntimer, A. E. Ramer-Tait, L. K. Petersen, K. A. Ross, K. A. Walz, C. Wang, J. Hostetter, B. Narasimhan, and M. J. Wannemuehler, Evaluation of biocompatibility and administration site reactogenicity of polyanhydride- particle-based platform for vaccine delivery. Adv. Healthcare Mater. 2, 369 (2013).
229. M. J. Kipper, J. H. Wilson, M. J. Wannemuehler, and B. Narasimhan, Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J. Biomed. Mater. Res. A 76, 798 (2006).
230. S. Y. Seong and P. Matzinger, Hydrophobicity: An ancient damageassociated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469 (2004).
231. L. Huntimer, J. H. Wilson Welder, K. Ross, B. Carrillo-Conde, L. Pruisner, C. Wang, B. Narasimhan, M. J. Wannemuehler, and A. E. Ramer-Tait, Single immunization with a suboptimal antigen dose encapsulated into polyanhydride microparticles promotes high titer and avid antibody responses. J. Biomed. Mater. Res. B 101, 91 (2013).
232. K. A. Ross, H. Loyd, W. Wu, L. Huntimer, M. J. Wannemuehler, S. Carpenter, and B. Narasimhan, Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles. J. Biomed. Mater. Res. A (2014), In press, DOI: 10.1002/jbm.a.35086.
233. K. A. Ross, H. Loyd, W. Wu, L. Huntimer, S. Ahmed, A. Sambol, S. Broderick, Z. Flickinger, K. Rajan, S. Hinrichs, T. Bronich, S. K. Mallapragada, M. J. Wannemuehler, S. Carpenter, and B. Narasimhan, Polyanhydride-based H5 hemagglutinin influenza nanovaccines elicit protective virus neutralizing titers and cellmediated immunity. Vaccine (2014), To be submitted.
234. H. M. Redhead, S. S. Davis, and L. Illum, Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation. J. Controlled Release 70, 353 (2001).
235. R. Singh and J. W. Lillard, Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86, 215 (2009).
236. V. B. Joshi, S. M. Geary, and A. K. Salem, Biodegradable particles as vaccine delivery systems: Size matters. AAPS J. 15, 85 (2013).
237. M. P. Desai, V. Labhasetwar, E. Walter, R. Levy, and G. L. Amidon, The mechanism of uptake of biodegradable microparticles in Caco- 2 cells is size dependent. Pharm. Res. 14, 1568 (1997).
238. R. Tellier, Review of aerosol transmission of influenza A virus. Emerg. Infect. Dis. 12, 1657 (2006).
239. T. Ku, S. Gill, R. Lobenberg, S. Azarmi, W. Roa, and E. J. Prenner, Size dependent interactions of nanoparticles with lung surfactant model systems and the significant impact on surface potential. J. Nanosci. Nanotechnol. 8, 2971 (2008).
240. C. Monfardini and M. Veronese, Stabilization of substances in circulation. Bioconjug. Chem. 9, 418 (1998).
241. M. O. Oyewumi, A. Kumar, and Z. Cui, Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. 9, 1095 (2011).
242. W. Zauner, N. A. Farrow, and A. M. Haines, In vitro uptake of polystyrene microspheres: Effect of particle size, cell line and cell density. J. Controlled Release 71, 39 (2001).
243. P. L. Mottram, D. Leong, B. Crimeen-Irwin, S. Gloster, S. D. Xiang, J. Meanger, R. Ghildyal, N. Vardaxis, and M. Plebanski, Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: Formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 4, 73 (2006).
244. S. M. Moghimi, A. C. Hunter, and J. C. Murray, Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53, 283 (2001).
245. S. M. Moghimi, Mechanisms of splenic clearance of blood cells and particles: Towards development of new splenotropic agents. Adv. Drug Deliv. Rev. 17, 103 (1995).
246. J. A. Champion, Y. K. Katare, and S. Mitragotri, Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J. Control Release 121, 3 (2007).
247. J. A. Champion, Y. K. Katare, and S. Mitragotri, Making polymeric micro- and nanoparticles of complex shapes. Proc. Natl. Acad. Sci. USA 104, 11901 (2007).
248. J.-W. Yoo and S. Mitragotri, Polymer particles that switch shape in response to a stimulus. Proc. Natl. Acad. Sci. USA 107, 11205 (2010).
249. C. He, Y. Hu, L. Yin, C. Tang, and C. Yin, Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31, 3657 (2010).
250. G. E. Price, M. R. Soboleski, C.-Y. Lo, J. A. Misplon, M. R. Quirion, K. V. Houser, M. B. Pearce, C. Pappas, T. M. Tumpey, and S. L. Epstein, Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2, and H1N1 viruses. PLoS ONE 5, e13162 (2010).
251. C. Von Garnier and L. P. Nicod, Immunology taught by lung dendritic cells. Swiss Med. Wkly 139, 186 (2009).
252. J. D. Crapo, A. G. Harmsen, M. P. Sherman, and R. A. Musson, Pulmonary immunobiology and inflammation in pulmonary diseases. Am. J. Respir. Crit. Care Med. 162, 1983 (2000).
253. N. Csaba, M. Garcia-Fuentes, and M. J. Alonso, Nanoparticles for nasal vaccination. Adv. Drug Deliver. Rev. 61, 140 (2009).
254. I. Jabbal-Gill, Nasal vaccine innovation. J. of Drug Targeting 18, 771 (2010).
255. M. M. Gaspar, U. Bakowsky, and C. Ehrhardt, Inhaled liposomes-current strategies and future challenges. J. Biomed. Nanotechnol. 4, 245 (2008).
256. R. Bi and N. Zhang, Liposomes as a carrier for pulmonary delivery of peptides and proteins. J. Biomed. Nanotechol. 3, 332 (2007).
257. S. Sharma, T. K. S. Mukkur, H. A. E. Benson, and Y. Chen, Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 98, 812 (2009).
258. H. Hasegawa, T. Ichinohe, A. Ainai, S.-I. Tamura, and T. Kurata, Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Ther. Clin. Risk Manag. 5, 125 (2009).
259. J. Sui, W. C. Hwang, S. Perez, G. Wei, D. Aird, L. M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N. J. Cox, L. A. Bankston, R. O. Donis, R. C. Liddington, and W. A. Marasco, Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265 (2009).
260. K. Kashyap, J. Steel, A. F. Oner, M. A. Dillon, R. E. Swale, K. M. Wall, K. J. Perry, A. Faynboym, M. Ilhan, M. Horowitz, L. Horowitz, P. Palese, R. R. Bhatt, and R. A. Lerner, Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. USA 105, 5986 (2008).
261. D. C. Ekiert, R. H. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F. Cox, H. J. Korse, B. Brandenburg, R. Vogels, J. P. Brakenhoff, R. Kompier, M. H. Koldijk, L. A. Cornelissen, L. L. Poon, M. Peiris, W. Koudstaal, I. A. Wilson, and J. Goudsmit, A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843 (2011).
262. F. Krammer and P. Palese, Universal influenza virus vaccines: Need for clinical trials. Nat. Immunol. 15, 3 (2014).
263. P. C. Doherty, S. J. Turner, R. G. Webby, and P. G. Thomas, Influenza and the challenge for immunology. Nat. Immunol. 7, 449 (2006).
264. P. G. Thomas, R. Keating, D. J. Hulse-Post, and P. C. Doherty, Cell-mediated protection in influenza infection. Emerg. Infect. Dis. 12, 48 (2006).
265. S. Liang, K. Mozdzanowska, G. Palladino, and W. Gerhard, Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152, 1653 (1994).
266. J. L. Nayak, K. A. Richards, F. A. Chaves, and A. J. Sant, Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins. Viral Immunol. 23, 169 (2010).
267. S. Sridhar, S. Begom, A. Bermingham, K. Hoschler, W. Adamson, W. Carman, T. Bean, W. Barclay, J. J. Deeks, and A. Lalvani, Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305 (2013).
268. D. L. Woodland and J. E. Kohlmeier, Migration, maintenance and recall of memory T cells in peripheral tissues. Nat. Rev. Immunol. 9, 153 (2009).
269. K. D. Klonowski, K. J. Williams, A. L. Marzo, D. A. Blair, E. G. Lingenheld, and L. Lefrancois, Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity 20, 551 (2004).
270. G. J. de Bree, E. M. van Leeuwen, T. A. Out, H. M. Jansen, R. E. Jonkers, and R. A. van Lier, Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J. Exp. Med. 202, 1433 (2005).
271. J. E. Kohlmeier, S. C. Miller, J. Smith, B. Lu, C. Gerard, T. Cookenham, A. D. Roberts, and D. L. Woodland, The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 29, 101 (2008).
272. B. Slutter, L. L. Pewe, S. M. Kaech, and J. T. Harty, Lung airwaysurveilling CXCR3hi memory CD8+ T cells are critical for protection against influenza A virus. Immunity 39, 939 (2013).
273. T. S. Kim, M. M. Hufford, J. Sun, Y. X. Fu, and T. J. Braciale, Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J. Exp. Med. 207, 1161 (2010).
274. J. McGill, N. Van Rooijen, and K. L. Legge, IL-15 transpresentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. J. Exp. Med. 207, 521 (2010).
275. J. McGill, N. Van Rooijen, and K. L. Legge, Protective influenzaspecific CD8 T cell responses require interactions with dendritic cells in the lungs. J. Exp. Med. 205, 1635 (2008).
276. J. E. McElhaney, Influenza vaccine responses in older adults. Ageing Res. Rev. 10, 379 (2011).
277. L. Haynes and S. L. Swain, Why aging T cells fail: Implications for vaccination. Immunity 24, 663 (2006).
278. P. A. Sheridan, H. A. Paich, J. Handy, E. A. Karlsson, M. G. Hudgens, A. B. Sammon, L. A. Holland, S. Weir, T. L. Noah, and M. A. Beck, Obesity is associated with impaired immune response to influenza vaccination in humans. Int. J. Obesity 36, 1072 (2012).
279. D. Frasca, A. Diaz, M. Romero, A. M. Landin, and B. B. Blomberg, Age effects on B cells and humoral immunity in humans. Ageing Res. Rev. 10, 330 (2011).
280. J. S. Lefebvre, A. C. Maue, S. M. Eaton, P. A. Lanthier, M. Tighe, and L. Haynes, The aged microenvironment contributes to the age-related functional defencts of CD4 T cells in mice. Aging Cell 11, 732 (2012).
281. B. Zheng, S. Han, Y. Takahashi, and G. Kelsoe, Immunosenescence and germinal center reaction. Immunol. Rev. 160, 63 (1997).
282. S. M. Eaton, E. M. Burns, K. Kusser, T. D. Randall, and L. Haynes, Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J. Exp. Med. 200, 1613 (2004).
283. A. Tamir, M. D. Eisenbraun, G. G. Garcia, and R. A. Miller, Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell/APC interaction. J. Immunol. 165, 1243 (2000).
284. K. Kedzierska, S. A. Valkenburg, P. C. Doherty, M. P. Davenport, and V. Venturi, Use it or lose it: Establishment and persistence of T cell memory. Frontiers in Immunology 3, 1 (2012).
285. E. J. Yager, M. Ahmed, K. Lanzer, T. D. Randall, D. L. Woodland, and M. A. Blackman, Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 205, 711 (2008).
286. J. E. McElhaney and R. B. Effros, Immunosenescence: What does it mean to health outcomes in older adults? Curr. Opinions Immunol. 21, 418 (2009).
287. B. A. Maletto, A. S. Ropolo, M. V. Liscovsky, D. O. Alignani, M. Glocker, and M. C. Pistoresi-Palencia, CpG oligodeoxinucleotides functions as an effective adjucant in aged BALB/c mice. Clin. Immunol. 117, 251 (2005).
288. A. C. Maue, S. M. Eaton, P. A. Lanthier, K. B. Sweet, S. L. Blumerman, and L. Haynes, Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J. Immunol. 182, 6129 (2009).
289. H. Asanuma, N. B. Zamri, S. Sekine, Y. Fukuyama, D. Tokuhara, R. S. Gilbert, T. Fukuiwa, K. Fujihashi, T. Sata, M. Tashiro, and K. Fujihashi, A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine 30, 803 (2012).
290. L. Haynes, S. M. Eaton, E. M. Burns, M. Rincon, and S. L. Swain, Inflammatory cytokines overcome age-related defencts in CD4 T cell responses in vivo. J. Immunol. 172, 5194 (2004).
291. A. Panda, F. Qian, S. Mohanty, D. van Duin, F. K. Newman, L. Zhang, S. Chen, V. Towle, R. B. Belshe, E. Fikrig, H. G. Allore, R. R. Montgomery, and A. C. Shaw, Age-assoicated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184, 2518 (2010).
292. D. van Duin, H. G. Allore, S. Mohanty, S. Ginter, F. K. Newman, R. B. Belshe, R. Medzhitov, and A. C. Shaw, Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine response in young and older adults. J. Infect. Dis. 195, 1590 (2007).
293. B. Lesourd, Nutritional factors and immunological aging. Proc. Nutr. Soc. 65, 319 (2006).
294. K. M. Chow, M. C. Law, C. B. Leung, C. C. Szeto, and P. K. Li, Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron. Clin. Pract. 103, c89 (2006).
295. J. A. Moynihan, M. R. Larson, J. Treanor, P. R. Duberstein, A. Power, B. Shore, and R. Ader, Psychosocial factors and the response to influenza vaccination in older adults. Psychosom. Med. 66, 950 (2004).
296. T. Ichinohe, I. K. Pang, Y. Kumamoto, D. R. Peaper, J. H. Ho, T. S. Murray, and A. Iwasaki, Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. 108, 5354 (2011).
297. S. Ng, D. K. Ip, V. J. Fang, K. H. Chan, S. S. Chiu, G. M. Leung, J. S. Peiris, and B. J. Cowling, The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children. Plos One 8, e59077 (2013).
298. K. D. Nath, J. G. Burel, V. Shankar, A. L. Pritchard, M. Towers, D. Looke, J. M. Davies, and J. W. Upham, Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 51 (2014).
299. E. Lawrence (ed.), Janeway's Immunobiology, Garland Science, New York (2008).
300. P. T. Tan, A. M. Khan, and J. T. August, Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability. Hum. Vaccin. 7, 402 (2011).
301. L. Moise, R. Tassone, H. Latimer, F. Terry, L. Levitz, J. P. Haran, T. M. Ross, C. Boyle, W. D. Martin, and A. S. DeGroot, Immunization with cross-conserved H1N1 influenza CD4+ T cell epitopes lowers viral burden in HLA DR3 transgenic mice. Hum. Vaccin. Immunother. 9, 2060 (2013).
302. X. Cheng, J. R. Zengel, A. L. Suguitan Jr, Q. Xu, W. Wang, J. Lin, and H. Jin, Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets. J. Infect. Dis. 208, 594 (2013).
303. H. Guo, F. Santiago, K. Lambert, T. Takimoto, and D. J. Topham, T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J. Virol. 85, 448 (2011).
304. J. E. McElhaney, X. Zhou, H. K. Talbot, E. Soethout, R. C. Bleackley, D. J. Granville, and G. Pawelec, The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 30, 2060 (2012).
305. T. M. Strutt, K. K. McKinstry, Y. Kuang, L. M. Bradley, and S. L. Swain, Memory CD4+ T cell-mediated protection depends on secondary effectors that are distinct from and superior to primary effectors. PNAS 109, E2551 (2012).
306. T. Knuschke, V. Sokolova, O. Rotan, M. Wadwa, M. Tenbusch, W. Hansen, P. Staeheli, M. Epple, J. Buer, and A. M. Westendorf, Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J. Immunol. 190, 6221 (2013).
307. Y. Phanse, B. R. Carrillo-Conde, A. E. Ramer-Tait, S. Broderick, C. S. Kong, K. Rajan, R. Flick, R. B. Mandell, B. Narasimhan, and M. J. Wannemuehler, A systems approach to designing next generation vaccines: Combining α-galactose modified antigens with nanoparticle platforms. Sci. Rep. 4, 3775 (2014).
308. L. M. Huntimer, K. A. Ross, R. J. Darling, N. E. Winterwood, P. Boggiatto, B. Narasimhan, A. E. Ramer-Tait, and M. J. Wannemuehler, Polyanhydride nanovaccine platform enhances antigen-specific cytotoxic T cell responses. Technology (2014), Submitted.
309. B. Carrillo-Conde, E. H. Song, A. Chavez-Santoscoy, Y. Phanse, A. E. Ramer-Tait, N. L. Pohl, M. J. Wannemuehler, B. H. Bellaire, and B. Narasimhan, Mannose-functionalized "pathogenlike" polyanhydride nanoparticles target C -type lectin receptors on dendritic cells. Mol. Pharm. 8, 1877 (2011).
310. Y. Phanse, B. R. Carrillo-Conde, A. E. Ramer-Tait, R. Roychoudhury, N. L. Pohl, B. Narasimhan, M. J. Wannemuehler, and B. H. Bellaire, Functionalization of polyanhydride microparticles with di-mannose influences uptake by and intracellular fate within dendritic cells. Acta Biomater. 9, 8902 (2013).
311. A. V. Chavez-Santoscoy, R. Roychoudhury, N. L. Pohl, M. J. Wannemuehler, B. Narasimhan, and A. E. Ramer-Tait, Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using "pathogen-like" amphiphilic polyanhydride nanoparticles. Biomaterials 33, 4762 (2012).
312. L. K. Petersen, Y. Phanse, A. E. Ramer-Tait, M. J. Wannemuehler, and B. Narasimhan, Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. Mol. Pharm. 9, 874 (2012).
313. J. Beran, I. A. Abdel-Messih, J. Raupachova, L. Hobzova, and E. Fragapane, A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin. Ther. 32, 2186 (2010).
314. A. Banzhoff, R. Gasparini, F. Laghi-Pasini, T. Staniscia, P. Durando, E. Montomoli, P. L. Capecchi, P. di Giovanni, L. Sticchi, C. Gentile, A. Hilbert, V. Brauer, S. Tilman, and A. Podda, MF59® -adjuvanted H5N1 vaccine induces mmmunologic Memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4, e4384 (2009).
315. D. I. Bernstein, K. M. Edwards, C. L. Dekker, R. Belshe, H. K. B. Talbot, I. L. Graham, D. L. Noah, F. He, and H. Hill, Effects of adjuvants on the safety and immunogenicity of an avian Influenza H5N1 vaccine in adults. J. Infect. Dis. 197, 667 (2008).
316. P. Lopez, Y. Caicedo, A. Sierra, S. Tilman, A. Banzhoff, and R. Clemens, Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: A phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J. Infect. Dis. 203, 1719 (2011).
317. T. Vesikari, A. Karvonen, S. Tilman, A. Borkowski, E. Montomoli, A. Banzhoff, and R. Clemens, Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126, e762 (2010).
318. G. Galli, D. Medini, E. Borgogni, L. Zedda, M. Bardelli, C. Malzone, S. Nuti, S. Tavarini, C. Sammicheli, A. K. Hilbert, V. Brauer, A. Banzhoff, R. Rappuoli, G. del Giudice, and F. Castellino, Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106, 3877 (2009).
319. G. Galli, K. Hancock, K. Hoschler, J. DeVos, M. Praus, M. Bardelli, C. Malzone, F. Castellino, C. Gentile, T. McNally, G. Del Giudice, A. Banzhoff, V. Brauer, E. Montomoli, M. Zambon, J. Katz, K. Nicholson, and I. Stephenson, Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl. Acad Sci. USA 106, 7962 (2009).
320. E. Fragapane, R. Gasparini, F. Schioppa, F. Laghi-Pasini, E. Montomoli, and A. Banzhoff, A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol. 17, 1817 (2010).
321. J. E. Ledgerwood, C. J. Wei, Z. Hu, I. J. Gordon, M. E. Enama, C. S. Hendel, P. M. McTamney, M. B. Pearce, H. M. Yassine, J. C. Boyington, R. Bailer, T. M. Tumpey, R. A. Koup, J. R. Mascola, G. J. Nabel, and B. S. Graham, DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11, 916 (2011).
322. K. M. Zangwill, J. J. Treanor, J. D. Campbell, D. L. Noah, and J. Ryea, Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J. Infect. Dis. 197, 580 (2008).
323. J. T. Lin, C. G. Li, X. Wang, N. Su, Y. Liu, Y. Z. Qiu, M. Yang, J. T. Chen, H. H. Fang, X. P. Dong, W. D. Yin, and Z. J. Feng, Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J. Infect. Dis. 199, 184 (2009).
324. R. C. Brady, J. J. Treanor, R. L. Atmar, W. A. Keitel, R. Edelman, W. H. Chen, P. Winokur, R. Belshe, I. L. Graham, D. L. Noah, K. Guo, and H. Hill, Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 27, 5091 (2009).
325. J. H. Beigel, J. Voell, C. Y. Huang, P. D. Burbelo, and H. C. Lane, Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J. Infect. Dis. 200, 501 (2009).
326. R. B. Belshe, S. E. Frey, I. Graham, M. J. Mulligan, S. Edupuganti, L. A. Jackson, A. Wald, G. Poland, R. Jacobson, H. L. Keyserling, P. Spearman, H. Hill, and M. Wolff, Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant. J. Infect. Dis. 203, 666 (2011).
327. N. A. Goji, C. Nolan, H. Hill, M. Wolff, D. L. Noah, T. B. Williams, T. Rowe, and J. J. Treanor, Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J. Infect. Dis. 198, 635 (2008).
328. I. Leroux-Roels, M. Van der Wielen, F. Kafeja, C. Vandermeulen, R. Lazarus, M. D. Snape, T. John, C. Carre, N. Nougarede, S. Pepin, G. Leroux-Roels, K. Hoppenbrouwers, A. J. Pollard, and P. Van Damme, Humoral and cellular immune responses to splitvirion H5N1 influenza vaccine in young and elderly adults. Vaccine 7, 6918 (2009).
329. T. F. Schwarz, T. Horacek, M. Knuf, H. G. Damman, F. Roman, M. Drame, P. Gillard, and W. Jilg, Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27, 6284 (2009).
330. S. Heijmans, M. De Meulemeester, P. Reynders, D. Giet, E. Demanet, P. Y. Devresse, G. Icardi, and M. Drame, Immunogenicity profile of a 3.75μ-g hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: A randomized trial. J. Infect. Dis. 203, 1054 (2011).
331. G. Risi, L. Frenette, J. M. Langley, P. Li, D. Riff, E. Sheldon, D. W. Vaughn, and L. Fries, Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months. Vaccine 29, 6408 (2011).
332. R. Fritz, N. Sabarth, S. Kiermayr, C. Hohenadl, M. K. Howard, R. Ilk, O. Kistner, H. J. Ehrlich, P. N. Barrett, and T. R. Kreil, A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J. Infect. Dis. 205, 28 (2012).
333. H. C. Rümke, J.-M. Bayas, J.-R. de Juanes, C. Caso, J. H. Richardus, M. Campins, L. Rombo, X Duval, V. Romaneko, T. F. Schwarz, R. Fassakhov, F. Abad-Santos, F. von Sonnenburg, M. Drame, R. Sanger, and W. R. Ballou, Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26, 2378 (2008).
334. N. Landry, B. J. Ward, S. Trépanier, E. Montomoli, M. Dargis, G. Lapini, and L. P. Vezina, Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5, e15559 (2010).
335. R. J. Cox, G. Pedersen, A. S. Madhun, S. Svindland, M. Sævik, L. Breakwell, K. Hoschler, M. Willemsen, L. Campitelli, J. K. Nostbakken, G. J. Weverling, J. Klap, K. C. McCullough, M. Zambon, R. Kompier, and H. Sjursen, Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29, 8049 (2011).
336. K. Levie, I. Leroux-Roels, K. Hoppenbrouwers, A.-D. Kervyn, C. Vandermeulen, S. Forgus, G. Leroux-Roels, S. Pichon, and I. Kusters, An Adjuvanted, Low-Dose, Pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces crossreactive immune responses in healthy adults. J. Infect. Dis. 198, 642 (2008).